Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...